Having assembled a large dataset of the Miro1 marker in both iPSCs (this paper) and fibroblasts (Hsieh et al., 2019) from PD patients and non-manifesting genetic carriers (Figures 1, 2 and Supplementary Table 1; Hsieh et al., 2019), we performed cross-sectional analyses of the overall outcome. This evidence concerns the gene RHOT1 and Parkinson disease.